Partner Headlines - BMY

  1. Strong Dollar Weakens Views

    IBD
  2. Drugmakers Warn On Dollar

    IBD
  3. Strong Dollar Pins U.S. Corporate Earnings Outlook

    IBD
  4. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  5. Strong Dollar Means Flabby Outlook For Some Overseas

    IBD
  6. Bristol, Pfizer, Novartis Forecasts Face FX Pressures

    IBD
  7. Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following ...

    Benzinga
  8. UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues ...

    Benzinga
  9. Earnings Scheduled For January 27, 2015

    Benzinga
  10. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus
  11. 3 High-Flying Health Care Stock IPOs To Watch In 2015

    IBD
  12. BRISTOL-MYERS SQUIBB

    IBD
  13. Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman

    Benzinga
  14. Feeling Good With This Med Company

    GuruFocus
  15. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  16. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  17. Celgene Outlook Is Upbeat

    IBD
  18. Celgene, Bristol-Myers Cancer Drug News Lifts Stocks

    IBD
  19. Bristol-Myers Hits 14-Year High On Cancer Drug Trial

    IBD
  20. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  21. Morning Market Gainers

    Benzinga
  22. Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2 ...

    Benzinga
  23. What Investors Should Expect From Portola Pharmaceutical's Upcoming ...

    Benzinga
  24. Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight ...

    Benzinga
  25. Bristol-Myers Squibb and California Institute for Biomedical ...

    Benzinga
  26. 5 Biotech Stocks With Big News Due In January

    IBD
  27. FDA's OKs may prescribe hits

    IBD
  28. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  29. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  30. Celgene drug could gain share

    IBD
  31. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD
  32. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD
  33. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga
  34. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus
  35. I think Zimmer Will Outperform S&P 500 Performance

    GuruFocus
  36. Avanir Stock Jumps On $3.5 Billion Otsuka Buyout

    IBD
  37. A Buy Recommendation From Absolute Valuation Model to Bristol-Myers ...

    GuruFocus
  38. Screening Pharma Stocks Amid Turnaround

    YCharts
  39. Incyte Building Blockbuster Drug One Disease At A Time

    IBD
  40. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus
  41. Merck Down On Hepatitis C Data; Gilead Rises

    IBD
  42. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus
  43. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb ...

    Benzinga
  44. Lung cancer drug promising

    IBD
  45. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD
  46. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  47. Eliquis revives Bristol-Myers

    IBD
  48. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  49. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  50. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  51. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  52. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  53. Earnings Scheduled For October 24, 2014

    Benzinga
  54. Must Watch Stocks for Today

    Benzinga
  55. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  56. Drug ETFs Attractive Buys On Pullback

    Benzinga
  57. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, ...

    GuruFocus
  58. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  59. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness
  60. The Six Types of Winning Stocks

    GuruFocus
  61. Markets Debut Week On Negative Note; S&P 500 Falls Through Key ...

    Benzinga
  62. Merck to release hep C data

    IBD
  63. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD
  64. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD
  65. Bristol-Myers pulls FDA filing

    IBD
  66. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD
  67. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws ...

    Benzinga
  68. 2 Mutual Funds Holding Hospital Stocks

    Benzinga
  69. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates ...

    Benzinga
  70. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...

    Benzinga
  71. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  72. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  73. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  74. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  75. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  76. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  77. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  78. Bristol-Myers Drug Gets OK

    IBD
  79. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  80. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  81. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  82. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  83. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  84. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  85. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  86. Drugmaker AstraZeneca Returns To Growth

    IBD
  87. The Stocks Already in Correction Mode

    FoxBusiness
  88. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  89. Bristol-Myers surprises Street

    IBD
  90. Thursday Morning Earnings Reports

    Benzinga
  91. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  92. Earnings Scheduled For July 24, 2014

    Benzinga
  93. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  94. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  95. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  96. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  97. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  98. Bristol seeks cancer drug nod

    IBD
  99. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  100. Japan approves BMY regimen

    IBD
Trading Center